JMP Securities Upgrades Infinity Pharmaceuticals To Market Outperform

Analysts at JMP Securities upgraded Infinity Pharmaceuticals

from Market Perform to Market Outperform. The target price for Infinity Pharmaceuticals is set to $24. Infinity Pharmaceuticals shares have dropped 22.09% over the past 52 weeks, while the S&P 500 index has gained 20.88% in the same period. Infinity Pharmaceuticals' shares jumped 44.05% to close at $15.73 yesterday.